ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 164

Haptoglobin Chains As Potential Biomarkers In Serum Of Osteoarthritis Disease

Carolina Fernandez-Costa1, Valentina Calamia1, Patricia Fernandez-Puente1, Jesus Mateos1, Beatriz Rocha2, Lucia Lourido1, Jose Luis Capelo3, Cristina Ruiz-Romero1,4 and Francisco J. Blanco1, 1Osteoarticular and Aging Research Laboratory, Proteomics Unit-Associated Node to ProteoRed-ISCIII, INIBIC-CHUAC, A Coruña, Spain, 2Grupo de Proteomica-PBR2-ProteoRed/ISCIII-Servicio de Reumatologia. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006., A Coruña, Spain, 3BIOSCOPE Group, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa,, Caparica, Portugal, 4CIBER-BBN, INIBIC-CHUAC, A Coruña, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Biomarkers, osteoarthritis and proteomics

  • Tweet
  • Email
  • Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

 

Background/Purpose: The aim of this study is to search for osteoarthritis (OA) biomarkers in human serum using an easy and fast approach and the validation of the potential biomarkers found with two independent methods.

Methods: The serum samples for the biomarker discovery experiment were obtained from 20 OA patients and 20 non-symptomatic controls. Samples were grouped into four pools of 10 samples each. The pools were subjected to a chemical sequential depletion protocol to reduce the high dynamic range of the proteins. Then, the proteomics comparison between OA and control sera was performed across two dimensional difference in-gel electrophoresis (2D-DIGE) experiment. The quantitative image analysis was performed using Same Spots software. For protein identification, gel spots were digested and analyzed by mass spectrometry (MALDI-TOF/TOF) and identified using Mascot with SwissProt knowledgebase.

Haptoglobin chains validation was performed with two different methods, immunoblotting and multiple reaction monitoring (MRM) technology with the QTRAP mass spectrometer.

Results: We studied the combination of a chemical sequential depletion method combined with 2D-DIGE for the search of OA biomarkers in 40 serum samples. The analysis resulted in 46 spots significantly and reproducibly altered between OA and control samples (29 increased and 17 decreased). These 46 spots correspond to 14 different proteins, Table 1. The most interesting result was the modulation of the protein haptoglobin (HPT), three different spots were opposite modulated and were identify as the three chains of haptoglobin. In human, HPT exists in two allelic forms that produce three known phenotypes. The presence of the different alpha chains in patients depends on which phenotype their express. Interestingly, HPT beta and HPT alpha-1 chains were increased in OA sera whereas HPT alpha-2 chain was decreased in OA sera versus control. Using western blot analysis and MRM mass spectrometry technique on 30 new individual samples from OA and control donors (15 from each condition), we confirmed the different modulations of the alpha and beta HPT chains.

Conclusion: We were able to identified 16 protein forms altered in the disease (9 increased and 7 decreased), and we verified for the first time the OA- dependent alteration of the haptoglobin chains. The haptoglobin protein provides two different OA biomarkers easily to measure in serum samples at the same time.

 


Disclosure:

C. Fernandez-Costa,
None;

V. Calamia,
None;

P. Fernandez-Puente,
None;

J. Mateos,
None;

B. Rocha,
None;

L. Lourido,
None;

J. L. Capelo,
None;

C. Ruiz-Romero,
None;

F. J. Blanco,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/haptoglobin-chains-as-potential-biomarkers-in-serum-of-osteoarthritis-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology